dc.contributor.author |
Altuntas, F |
|
dc.contributor.author |
Ata, N |
|
dc.contributor.author |
Yigenoglu, TN |
|
dc.contributor.author |
Basci, S |
|
dc.contributor.author |
Dal, MS |
|
dc.contributor.author |
Korkmaz, S |
|
dc.contributor.author |
Namdaroglu, S |
|
dc.contributor.author |
Basturk, A |
|
dc.contributor.author |
Hacibekiroglu, T |
|
dc.contributor.author |
Dogu, MH |
|
dc.contributor.author |
Berber, I |
|
dc.contributor.author |
Dal, K |
|
dc.contributor.author |
Erkurt, MA |
|
dc.contributor.author |
Turgut, B |
|
dc.contributor.author |
Ulgu, MM |
|
dc.contributor.author |
Celik, O |
|
dc.contributor.author |
Akunal, A |
|
dc.contributor.author |
Birinci, S |
|
dc.date.accessioned |
2022-10-05T13:20:13Z |
|
dc.date.available |
2022-10-05T13:20:13Z |
|
dc.date.issued |
2021 |
|
dc.identifier.uri |
http://hdl.handle.net/11616/62730 |
|
dc.description.abstract |
In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients. |
|
dc.description.abstract |
C1 [Altuntas, Fevzi; Yigenoglu, Tugce Nur; Basci, Semih; Dal, Mehmet Sinan] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Dept Hematol, Ankara, Turkey. |
|
dc.description.abstract |
[Altuntas, Fevzi; Yigenoglu, Tugce Nur; Basci, Semih; Dal, Mehmet Sinan] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Bone Marrow Transplantat Ctr, Ankara, Turkey. |
|
dc.description.abstract |
[Altuntas, Fevzi] Yildirim Beyazit Univ, Dept Internal Med, Div Hematol, Ankara, Turkey. |
|
dc.description.abstract |
[Ata, Naim] Minist Hlth, Dept Strategy Dev, Ankara, Turkey. |
|
dc.description.abstract |
[Korkmaz, Serdal] Univ Hlth Sci, Kayseri Training & Res Hosp, Dept Hematol, Kayseri, Turkey. |
|
dc.description.abstract |
[Namdaroglu, Sinem] Univ Hlth Sci, Bozyaka Training & Res Hosp, Dept Hematol, Izmir, Turkey. |
|
dc.description.abstract |
[Basturk, Abdulkadir] Selcuk Univ, Sch Med, Dept Internal Med, Div Hematol, Konya, Turkey. |
|
dc.description.abstract |
[Hacibekiroglu, Tuba] Sakarya Univ, Sch Med, Dept Internal Med, Div Hematol, Sakarya, Turkey. |
|
dc.description.abstract |
[Dogu, Mehmet Hilmi] Istanbul Training & Res Hosp, Dept Hematol, Istanbul, Turkey. |
|
dc.description.abstract |
[Berber, Ilhami; Erkurt, Mehmet Ali] Inonu Univ, Sch Med, Dept Internal Med, Div Hematol, Malatya, Turkey. |
|
dc.description.abstract |
[Dal, Kursat] Kecioren Training & Res Hosp, Dept Internal Med, Ankara, Turkey. |
|
dc.description.abstract |
[Turgut, Burhan] Namik Kemal Univ, Sch Med, Dept Internal Med, Div Hematol, Tekirdag, Turkey. |
|
dc.description.abstract |
[Ulgu, Mustafa Mahir; Akunal, Abdullah] Minist Hlth, Gen Directorate Hlth Informat Syst, Ankara, Turkey. |
|
dc.description.abstract |
[Celik, Osman] Minist Hlth, Publ Hosp Gen Directorate, Ankara, Turkey. |
|
dc.description.abstract |
[Birinci, Suayip] Hlth, Ankara, Turkey. |
|
dc.source |
BONE MARROW TRANSPLANTATION |
|
dc.title |
COVID-19 in hematopoietic cell transplant recipients |
|